CTLA4 and neoplasm: Immune checkpoint inhibitors (ICIs), including programmed cell death-1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte antigen 4 (CTLA4) inhibitors [69], are a modality of tumor immunotherapy.